[Treatment of painful bony metastases with Samarium 153-EDTMP in prostate carcinoma].
THE OBJECTIVE of this work is to evaluate a new therapy, the metabolic radiotherapy to the 153Samarium-EDTMP, of recent introduction in Tunisia, in the painful bony metastasis treatment observed at the patients affected of cancer of the prostate.


METHODS
It is about a retrospective survey with a receding of 40 months, achieved through 45 files of patients having benefited all of this new treatment for painful bony metastases in relation with a prostatic adenocarcinoma and collected by three centers of Nuclear Medicine of the capital: the institute Salah Azaiez (state-controlled), the Center CERU (deprives) and the Military hospital (HMPIT).


RESULTS
We tried to appreciate essentially four parameters: the therapeutic efficiency, the factors influencing the answer in the treatment, the toxicity of the treatment and the sources of failure. We observed a positive answer in 92,1% of the cases, this answer was complete in 36,5% of the cases. The results gotten after multiple administrations show that the cures could be repeated with results comparable to those of the first cure. The therapeutic efficiency is at least equivalent to those of the other therapeutic means, with nearly non-existent secondary effects. The only toxicity is of hematological order; it is the most often moderate and reversible with a complete recuperation at the end of 8 weeks. Besides, the effect on the pain came with an improvement of the quality of life of the patients treaties.


CONCLUSIONS
Its precocious introduction in the taken in charge of the metastatic patients, would allow them to benefit better from its efficiency, simplicity and weak toxicity and therefore to enjoy a better quality of life.
Service de Médecine Nucléaire, Institut Salah Azaïez, Tunis.
Aida
A
Mhiri
Rim
R
Hassad
Ali
A
Sellem
Haifa
H
Bahri
Rouillah
R
Diakite
Ihsen
I
Slim
Majdi
M
Mahersi
Hatem
H
Hammami
Mansour
M
Ben Adallah
Mohamed Faouzi
MF
Ben Slimene
D000368:Aged; D000369:Aged, 80 and over; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010148:Intractable Pain / Q000532:radiotherapy*; D011471:Prostatic Neoplasms / Q000473:pathology*; D011868:Radioisotopes / Q000627:therapeutic use; D012189:Retrospective Studies
D018712:Analgesics, Non-Narcotic; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; C061972:samarium Sm-153 lexidronam